Ergebnis der Suchanfrage nach Celle

Orte

Alle 16 Treffer anzeigenweniger anzeigen

Hustedt (Celle)Landkreis Celle Nienhagen (Landkreis Celle)Stadt Celle Altencelle Westercelle

Themen

Excellence Award HR Excellence Award HR Excellence Awards

Inhalte

Neueste Relevanteste

Filtern

582 Treffer

28.06.2005 – 08:36
Finanzen
BWT AG
euro adhoc: BWT Aktiengesellschaft / Mergers - Acquisitions - Takeovers / BWT AKTIENGESELLSCHAFT IS PLANNING TO SPIN OFF CHRIST WATER TECHNOLOGY AG WITH ITS BUSINESS DIVISION AQUA SYSTEMS TECHNOLOGIES
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 27.06.2005 Mondsee, 28 June 2005: BWT Aktiengesellschaft, Europe's market leader in the water treatment sector, is planning to spin off its wholly owned subsidiary Christ Water Technology AG ...
mehr
23.06.2005 – 13:53
Wirtschaft
Boehringer Ingelheim
U.S. FDA Approves New Anti-HIV Drug Aptivus(R) for Use in Combination Therapy
Ridgefield, Connecticut (ots/PRNewswire) - - The Following Press Release Was Issued By Our U.S. Affiliate Boehringer Ingelheim Pharmaceuticals, Inc. in The United States on June 23, 2005 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Aptivus(R) (tipranavir) ...
mehr
13.05.2005 – 08:33
Finanzen
BWT AG
euro adhoc: BWT Aktiengesellschaft / Quarterly or Semiannual Financial Statements / BWT makes budget for first quarter of 2005
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 11.05.2005 BWT - the Best Water Technology Group - has made a good start to the 2005 financial year, achieving a 15 % increase in earnings and continued high levels of sales. Consolidated ...
mehr
28.02.2005 – 08:03
Finanzen
Boehringer Ingelheim
Efficacy of Investigational Anti-HIV Agent Tipranavir Demonstrated by New Data
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
mehr
18.11.2004 – 12:25
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Announces 24-Week Results From Second Phase III Pivotal Study of Tipranavir
Glasgow, Scotland, November 18 (ots/PRNewswire) - - RESIST-2 Data Demonstrate Efficacy in Treatment-Experienced Patient Population New tipranavir pivotal Phase III data show that a statistically significant higher percentage of treatment-experienced HIV-positive patients taking tipranavir therapy achieved treatment response versus those taking other ...
mehr
01.11.2004 – 14:14
Wirtschaft
Boehringer Ingelheim
Boehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study
Washington, November 1 (ots/PRNewswire) - New data from a pivotal Phase 3 study (RESIST-1) demonstrate that a statistically significant greater percentage of HIV-positive patients taking a tipranavir-based regimen achieved a treatment response versus those taking a regimen containing one of several marketed protease inhibitors (PIs). Treatment response in this study ...
mehr

10.09.2003 – 13:29
Wirtschaft
Mazda
World Premiere of the New Mazda3 at the International Motor Show in Frankfurt
mehr
25.03.2003 – 22:06
Finanzen
Medigene AG
euro adhoc: MediGene AG / MediGene discontinues development of CVLP tumor vaccine (E)
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Martinsried/San Diego, March 25, 2003. The biopharmaceutical company MediGene AG (TechDax30: MDG) will discontinue the development project of a CVLP tumor vaccine against cervical cancer. The data obtained from a clinical phase 1/2 trial with the ...
mehr
02.11.2001 – 12:21
Panorama
ScheBo Biotech AG
The Forgotten Organ - Why to Screen for Exocrine Pancreatic Malfunction with respect to Diabetes Mellitus! / Tumour Metabolism - A Novel Concept Closes a Clinical Gap!
Giessen, Germany (ots) - Diabetes mellitus and cancer are among the diseases of greatest clinical focus. At the ScheBo Biotech AG Symposium during MEDICA on the occasion of the World Congress of Pathology and Laboratory Medicine (WASPaLM) 2001 two specific diagnostic tools with unique clinical approaches will be ...
mehr
12.07.2001 – 10:10
Wirtschaft
Bertelsmann SE & Co. KGaA
Hartmut Ostrowski appointed to Bertelsmann AG Executive Board as successor to Gunter Thielen / Head of successful Bertelsmann Services Group to head up Arvato as of September 2002 - growth and excellent customer service as top priorities
Gütersloh (ots) - The Bertelsmann AG Supervisory Board has appointed Hartmut Ostrowski, 43, as a deputy member of the Bertelsmann Executive Board, effective October 1, 2001. Ostrowski is scheduled to become a regular Executive Board member on September 1, 2002. He will then become the successor to Gunter ...
mehr
30.04.2001 – 08:13
ADVA Optical Networking SE
ots Ad hoc-Service: ADVA AG <DE0005103006> ADVA OPTICAL NETWORKING REPORTS 2000 FINANCIAL RESULTS
Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. Internet: ...
mehr
20.04.2001 – 15:02
BWT AG
ots Ad hoc-Service: BWT AG <AT0000737705>BWT BUSINESS DEVELOPMENT IN 2000 RECORD RESULT FORMS THE BASIS FOR DYNAMIC INTERNATIONALISATION
Ad hoc-announcement. The sender is solely responsible for the contents of this announcement. Internet: ...
mehr

Vorherige11121314151617181920